NCT00003501View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 10, 1996

Primary Completion Date

July 2, 2003

Study Completion Date

July 2, 2003

Conditions
Non-hodgkins Lymphoma
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER